Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Par Drugs and Chemicals Limited ( (IN:PAR) ) just unveiled an announcement.
Par Drugs and Chemicals Limited held its 26th Annual General Meeting on September 27, 2025, chaired by Mr. Falgun V. Savani. The meeting highlighted the company’s financial performance, noting an increase in total revenue to ₹10,312.38 lakh for FY25, up from ₹9,588.27 lakh in FY24, driven by higher operational revenue. However, profit before tax decreased to ₹1,792.29 lakh due to rising material costs, and net profit slightly declined to ₹1,335.79 lakh. The meeting also discussed strategic transitions aimed at enhancing the company’s market positioning.
More about Par Drugs and Chemicals Limited
Par Drugs and Chemicals Limited operates in the pharmaceutical industry, focusing on the production and distribution of various chemical products. The company is known for its contributions to the pharmaceutical supply chain, primarily serving markets that require high-quality chemical compounds.
Average Trading Volume: 8,561
Technical Sentiment Signal: Sell
See more insights into PAR stock on TipRanks’ Stock Analysis page.